Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Kamada Ltd.
483
•Kamada Ltd.•March 2, 2023

Kamada Ltd. – FDA 483, Mar 2, 2023

Record Details

During an FDA inspection conducted from February 22 to March 02, 2023, Kamada Ltd., a drug substance and drug product manufacturer, received a Form 483 listing several significant observations indicating non-compliance with regulatory expectations. The inspection, carried out under the Federal Food, Drug, and Cosmetic Act, identified critical issues in manufacturing practices and facility maintenance. Key observations included inadequate process validation, particularly concerning equipment use and the implementation of unvalidated "amended" procedures without proper regulatory submission or impact evaluation. For instance, specific manufacturing runs utilized non-qualified or unvalidated procedural versions, and critical process deviations were allowed to proceed without adequate corrective action. Facility conditions were also a concern, with reports of numerous power outages, recurrent water leaks affecting production areas, and frequent pressure differential excursions. These issues suggest a lack of robust facility control and maintenance. Furthermore, aseptic filling procedures exhibited deficiencies, such as product spills during critical runs not being adequately addressed in subsequent media fill studies, and insufficient environmental monitoring during product transfer line connections. Finally, the company lacked adequate written procedures for labeling drug substances, posing a risk of mix-ups. Kamada Ltd. is required to address these observations by implementing comprehensive corrective and preventive actions to ensure product quality and compliance.

Company
Kamada Ltd.
Inspection date
March 2, 2023
Product type
biologics
Office
Baltimore District Office
People
  • Prajakta A. Varadkar
  • Zhihao Peter Qiu (Supervisory Biologist)
  • Peter Boboris
  • Pete Amin (FDA_PERSONNEL)
  • Olga Simakova
View Company Profile

ID · e0fa6991-c93b-47e2-8f93-7883edc6555b

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Kamada Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.